鳖甲消癥丸联合拉米夫定治疗慢性乙型肝炎的疗效观察

罗建君; 周帅

鳖甲消癥丸联合拉米夫定治疗慢性乙型肝炎的疗效观察

罗建君,
周帅

肇庆市中医院内二科

详细信息

中图分类号: R512.62
计量
- 文章访问数: 2804
- HTML全文浏览量: 19
- PDF下载量: 612
- 被引次数: 0
出版历程
- 出版日期: 2013-04-20

Clinical study of lamivudine and Biejia Xiaozheng pill combination therapy for chronic hepatitis B

摘要

摘要:
目的观察鳖甲消癥丸联合拉米夫定治疗慢性乙型肝炎(CHB)的临床疗效及优势。方法收集轻中度CHB患者72例,随机分成2组。拉米夫定对照组30例,单以拉米夫定治疗;联合治疗组42例,在拉米夫定治疗基础上前24周连续加服鳖甲消癥丸2粒,2次/d。治疗前及治疗后的第12、24、48周检测并对比血清ALT、TBil、HBV DNA定量等指标变化,并对比临床症状体征变化,第24和48周评价总体疗效。结果 24周时联合治疗组症状学疗效及病毒完全应答率均显著优于对照组;治疗24周时联合治疗组HBV DNA定量显著低于对照组,治疗12及48周时差异无统计学意义;同组治疗后各时间点ALT、TBil与治疗前比较差异均有统计学意义(P<0.05),治疗的前24周两项指标变化显著,后24周两项指标变化不显著。结论鳖甲消癥丸可增进拉米夫定治疗的早期快速应答,从而提高临床疗效,甚至减少耐药的发生。
- 肝炎,乙型,慢性 /
- 鳖甲消癥丸 /
- 拉米夫定 /
- 中西医结合疗法
Abstract:
Objective To investigate whether supplementation of Biejia Xiaozheng pill increased the therapeutic benefit of lamivudine (LAM) nucleoside analogue drug treatment in patients with chronic hepatitis B virus (HBV) infection.Methods Between June 2009 and June 2012, adult patients (18-60 years old) with mild to moderate chronic hepatitis B (CHB) were recruited for study according to findings of: serum HBV DNA ≥105 copies/ml, alanine aminotransferase (ALT) and asparatate aminotransferase (AST) increased<10 times="" the="" upper="" limit="" of="" normal="" total="" bilirubin="">5 times the ULN, and no previous treatment with antiviral and immunomodulatory agents.The 72 enrollees were randomly assigned to receive LAM alone for 24 weeks (control group, n=30) or LAM combined with Biejia Xiaozheng pill for 24 weeks followed by peresistant Biejia Xiaozheng pill (combination therapy group, n=42) .The baseline levels of serum ALT, TBil, and HBV DNA were compared between the two groups at weeks 12, 24 and 48 after treatment initiation.The overall efficacy was evaluated at weeks 24 and 48, and classified as: complete response, when ALT and TBil returned to normal level and HBV DNA was undetectable;partial response, when ALT and TBil showed ≥50% reduction and HBV DNA was reduced to ≥2log10 copies/ml;non-response: ALT and TBil ≤50% reduction and HBV DNA was reduced to ≤2log10 copies/ml or increased.The sigifinficance of differences between the control and combination therapy groups was assessed by Chi-squared test or t-test.Results At week 24 of treatment, a significantly higher percentage of the combined treatment group than the control group had achieved complete response (80.95 vs.56.67%, P<0.05) 48="" but="" at="" week="" the="" two="" groups="" showed="" similar="" percentages="" of="" complete="" response="" 83.33="" p="">0.05) .A similar trend of significant reduction in HBV DNA quantity was observed at 24 weeks of treatment (2.53±0.61 vs.3.12±0.54, P<0.01) 48="" and="" not="" at="" weeks="" of="" treatment="" 0.85="" p="">0.05) .ALT level was also significantly improved in the combination therapy group at 24 weeks compared to the control group (32.24±6.42 vs.45.10±5.44 U/L, P<0.01) 48="" but="" not="" at="" weeks="" of="" treatment="" p="">0.05) .However, the combination therapy group showed significantly improved TBil levels at both week 24 of treatment (12.66±3.41 vs.15.42±5.76 μmol/L, P<0.01) and week 48 of treatment (11.22±3.62 vs.13.86±4.88 μmol/L, P<0.01) .Conclusion Supplementation of Biejia Xiaozheng pill to the standard LAM therapy can enhance the early and rapid virological response rate, and may help to reduce the occurrence of LAM resistance.
- hepatitis B /
- chronic /
- Biejia Xiaozheng pill /
- lamivudine

HTML全文

参考文献(9)

[1]Chinese Society of Hepatology, Chinese Medical Association.Chi-nese Society of Infectious Diseases, Chinese Medical Associa-tion.The guideline of prevention and treatment for chronic hepati-tis B[J].J Clin Hepatol, 2006, 22 (1) :3-15. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南[J].临床肝胆病杂志, 2006, 22 (1) :3-15.

[2]Li LQ, Huang SY, Bin JP, et al.Clinical efficacy of Biejiaxi-aozheng pills in treatment of chronic hepatitis B[J].PractTradit Chin Intern Med, 1998, 12 (3) :42, 45. (in Chinese) 李力强, 黄胜英, 宾建平, 等.鳖甲消症丸治疗慢性乙型肝炎的临床观察[J].实用中医内科杂志, 1998, 12 (3) :42, 45.

[3]Li LQ, Huang SY, Bin JP, et al.Clinical study of Biejiaxi-aozheng pills in preventing esophageal and gastric varicesbleeding in patients with cirrhosis[J].Chin J Integr TraditWest Med on Liver, 2000, S1:81-83. (in Chinese) 李力强, 黄胜英, 宾建平, 等.鳖甲消癥丸预防肝硬变患者食道胃底静脉曲张破裂出血的临床研究[J].中西医结合肝病杂志, 2000, S1:81-83.

[4]Huang SY, Wu T, Li LQ, et al.Experimental study of the effectsagainst hepatic fibrosis of biejiaxiaozheng pills[J].J Beijing UnivChin Med, 2004, 27 (5) :56-58, 96. (in Chinese) 黄胜英, 吴铁, 李力强, 等.鳖甲消癥丸抗大鼠肝纤维化的实验研究[J].北京中医药大学学报, 2004, 27 (5) :56-58, 96.

[5]Ni Q, Liu KZ.Current issues of antiviral therapy for chronic hepati-tis B[J].J Clin Hepatol, 2012, 28 (3) :172-175. (in Chinese) 倪勤, 刘克洲.慢性乙型肝炎抗病毒治疗若干热点[J].临床肝胆病杂志, 2012, 28 (3) :172-175.

[6] Ren N, Yan J, Cai HD, et al.The observation of 96 weeksefficacy of lamividine plus adefovir combination initial therapyfor HBeAg positive chronic hepatitis B[J].Int J virol, 2012, 19 (3) :113-117. (in Chinese) 任娜, 闫杰, 蔡晧东, 等.拉米夫定与阿德福韦酯初始联合治疗HBeAg阳性慢性乙型肝炎96周疗效观察[J].国际病毒学杂志, 2012, 19 (3) :113-117.

[7]Yao LF, Zhu Q, Lin CW, et al.Early HBV DNA response isan important predictor for lamivudine treatment of patientswith HBeAg positive chronic hepatitis B[J].J Clin Hepatol, 2007, 10 (1) :8-11. (in Chinese) 姚履枫, 朱琪, 林彩文, 等.早期病毒学应答是评估拉米夫定治疗慢性乙型肝炎疗效的重要指标[J].实用肝脏病杂志, 2007, 10 (1) :8-11.

[8]Peng JP, Sun KW, Wu YN.Impact of early virological re-sponse to antiviral treatment on the outcomes of hepatitis B-associated liver failure[J].J Clin Hepatol, 2012, 28 (10) :752-755. (in Chinese) 彭建平, 孙克伟, 伍玉南.早期病毒学应答对乙型肝炎病毒感染相关肝衰竭患者预后及转归的影响[J].临床肝胆病杂志, 2012, 28 (10) :752-755.

[9]Yuen MF, Fung J, Seto WK, et al.Combination of baselineparameters and on-treatment hepatitis B virus DNA leves tostart and continue patients with lamivudine therapy[J].Anti-vir Ther, 2009, 14 (5) , 679-685.

施引文献

资源附件(0)

访问统计